PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Status:
Withdrawn
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating
metastatic advanced renal cancer. Blood samples will also be collected for research purposes.